A Pilot Study Examining the Effects of Tolvaptan on Residual Renal Function in Peritoneal Dialysis for Diabetics.

about

Advances in Understanding and Management of Residual Renal Function in Patients with Chronic Kidney Disease.Preservation of Residual Kidney Function and Urine Volume in Patients on Dialysis.

P2860

Q39148711-3F04A96E-E50B-4219-BA0B-4A1D7745C42D Q54866053-F0A4ABC1-D55C-4235-9669-5618A3400000

P2860

A Pilot Study Examining the Effects of Tolvaptan on Residual Renal Function in Peritoneal Dialysis for Diabetics.

Item

http://www.wikidata.org/entity/Q41109886

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

A Pilot Study Examining the Ef ...... toneal Dialysis for Diabetics.

@en

type

Item

label

A Pilot Study Examining the Ef ...... toneal Dialysis for Diabetics.

@en

prefLabel

A Pilot Study Examining the Ef ...... toneal Dialysis for Diabetics.

@en

P1476

A Pilot Study Examining the Ef ...... toneal Dialysis for Diabetics.

@en

P2093

Akinori Hobo

http://www.w3.org/2001/XMLSchema#string

Koki Kabu

http://www.w3.org/2001/XMLSchema#string

Shinji Furuta

http://www.w3.org/2001/XMLSchema#string

Takahiro Hayasaki

http://www.w3.org/2001/XMLSchema#string

Takeyuki Hiramatsu

http://www.w3.org/2001/XMLSchema#string

P2860

Protein kinase A phosphorylation is involved in regulated exocytosis of aquaporin-2 in transfected LLC-PK1 cells

Hypertension in continuous ambulatory peritoneal dialysis patients: what do we know and what can we do about it?

Chronic peritoneal dialysis in the elderly: a review.

Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial.

Malnutrition, inflammation, and atherosclerosis in peritoneal dialysis patients.

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.

Complementary dialysis for daily dialysis.

The "heart" of peritoneal dialysis.

Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure

Effects of tolvaptan on dyspnoea relief from the EVEREST trials.

P304

552-558

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/PDI.2013.00290

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25082843

http://www.w3.org/2001/XMLSchema#string

P921

renal dialysis

P932

4597988

http://www.w3.org/2001/XMLSchema#string

A Pilot Study Examining the Effects of Tolvaptan on Residual Renal Function in Peritoneal Dialysis for Diabetics.

about

P2860

P2860

A Pilot Study Examining the Effects of Tolvaptan on Residual Renal Function in Peritoneal Dialysis for Diabetics.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932